Basel, Switzerland

Ulrich Zutter

USPTO Granted Patents = 14 

 

 

Average Co-Inventor Count = 2.5

ph-index = 3

Forward Citations = 63(Granted Patents)


Company Filing History:


Years Active: 1993-2017

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):

Title: Ulrich Zutter: Innovator in Pharmaceutical Processes

Introduction

Ulrich Zutter is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, holding a total of 14 patents. His work primarily focuses on innovative processes for the manufacture of various chemical compounds.

Latest Patents

Among his latest patents is a process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide. This invention provides methods to produce crystalline forms of this compound, which are essential for pharmaceutical applications. Another notable patent involves the preparation of proline derivatives, which are preferential inhibitors of the cysteine protease Cathepsin S. These derivatives are particularly useful in treating metabolic diseases such as diabetes and atherosclerosis.

Career Highlights

Ulrich Zutter has worked with renowned companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to develop and refine his innovative processes, contributing to advancements in drug development.

Collaborations

Throughout his career, Zutter has collaborated with notable professionals in the field, including Michelangelo Scalone and Martin Karpf. These partnerships have further enhanced his research and development efforts.

Conclusion

Ulrich Zutter's contributions to pharmaceutical innovations demonstrate his expertise and commitment to advancing medical science. His patents reflect a deep understanding of chemical processes and their applications in treating significant health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…